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Non-small cell lung cancers (NSCLC), in particular adenocarcinoma, are often mixed with normal cells. Therefore, low sensitivity of
direct sequencing used for K-Ras mutation analysis could be inadequate in some cases. Our study focused on the possibility to
increase the detection of K-Ras mutations in cases of low tumour cellularity. Besides direct sequencing, we used wild-type
hybridisation probes and peptide-nucleic-acid (PNA)-mediated PCR clamping to detect mutations at codons 12 and 13, in 114
routine consecutive NSCLC frozen surgical tumours untreated by targeted drugs. The sensitivity of the analysis without or with PNA
was 10 and 1% of tumour DNA, respectively. Direct sequencing revealed K-Ras mutations in 11 out of 114 tumours (10%). Using
PNA-mediated PCR clamping, 10 additional cases of K-Ras mutations were detected (21 out of 114, 18%, Po0.005), among which
five in samples with low tumour cellularity. In adenocarcinoma, K-Ras mutation frequency increased from 7 out of 55 (13%) by direct
sequencing to 15 out of 55 (27%) by clamped-PCR (Po0.005). K-Ras mutations detected by these sensitive techniques lost its
prognostic value. In conclusion, a rapid and sensitive PCR-clamping test avoiding macro or micro dissection could be proposed in
routine analysis especially for NSCLC samples with low percentage of tumour cells such as bronchial biopsies or after neoadjuvant
chemotherapy.
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Malignant transformations are the result of an accumulation of
carcinogenesis steps corresponding to activation of oncogenes and
inactivation of tumour suppressor genes (Bishop, 1991). Among
the available candidates, the K-Ras proto-oncogene is the most
well-studied cellular gene whose alterations seem to have an
important role in the pathogenesis of human cancer. K-Ras
oncogene is a known downstream signaling molecule in the EFGR-
signaling pathway. K-Ras gene encodes a 21kDa GTP-binding
protein, which controls the mechanisms of cell growth and
differentiation. Point mutations in the K-Ras gene lead to
uncontrolled stimulation of Ras-related functions by altered
p21ras protein, locking it in the ‘on’ position for signal
transduction (Adjei, 2001; Molina and Adjei, 2007).
Non-small cell lung cancers (NSCLC) represent more than 80%
of lung cancers and are subgrouped in squamous cell carcinomas
(SCC), adenocarcinoma (ADC) and large cell carcinoma (Travis
et al, 2004). K-Ras mutations are found in 10–20% of NSCLC and
have been described in approximately 30% of ADC (Ahrendt et al,
2001). About 92% of K-Ras mutations occur in codon 12
(Huncharek et al, 1999). K-Ras mutations are most closely
associated with a history of cigarette smoking and are more
common in women (Ahrendt et al, 2001; Broermann et al, 2002;
Sugio et al, 2006; Tam et al, 2006). Oncogenic activation of K-Ras
has been reported as a prognostic marker of poor outcome in
NSCLC patients and K-Ras mutations seemed to be associated with
a shorter survival in early-stage and locally advanced NSCLC
(Fukuyama et al, 1997; Huncharek et al, 1999). A recent meta-
analysis of K-Ras mutations in lung cancer showed that these
mutations appeared to be associated with shorter survival in
NSCLC (Mascaux et al, 2005). It was also suggested that K-Ras
mutations could be predictive of chemotherapy resistance, in
metastatic disease rather in adjuvant situation (Eberhard et al,
2005; Tsao et al, 2007). Although meta-analyses has indicated that
K-Ras gene mutations are weak prognostic markers of poorer
outcome in NSCLC, results from individual studies have been
inconsistent (Huncharek et al, 1999; Mascaux et al, 2005; Tsao
et al, 2007).
At first, EGFR status is a decisive molecular factor for using
EGFR-targeted therapies in NSCLC (Lynch et al, 2004; Paez et al,
2004; Pao et al, 2004). K-Ras and EGFR mutations were shown to
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sbe mutually exclusive in lung ADC (Kosaka et al, 2004). Mutations
in K-Ras are found more frequently in patients who develop
disease progression upon gefinitib or erlotinib therapy (Pao et al,
2005). Both the time to disease progression and the median
survival were significantly worse in patients with K-Ras mutations
when they were treated with erlotinib in combination with
chemotherapy compared with those receiving chemotherapy alone
(Eberhard et al, 2005). It was suggested that one potential
mechanism for primary resistance to EGFR-TKI may be the
presence of K-Ras mutations (Massarelli et al, 2007). These recent
advances within molecular biology may facilitate treatment
selection based on potential predictive molecular markers such
as K-Ras.
Direct sequencing is considered as the gold standard and has
allowed comprehensive knowledge of mutations (Lynch et al, 2004;
Paez et al, 2004; Pao et al, 2004, 2005; Massarelli et al, 2007).
Direct sequencing is still widely employed to discover ‘new’
mutations. But the sensitivity of direct sequencing depends on the
percentage of tumour cells in the analysed sample. A percentage
of more than 50% of tumour cells is usually requested and
the threshold of detection is around 25% of mutant DNA into a
wild-type environment (Pao and Ladanyi, 2007; Eberhard et al,
2008). If a low percentage of tumour cells is present in some
samples, direct sequencing could lead to false-negative results.
Thus, direct sequencing considered as the gold standard
could be inadequate in such cases, even in surgical specimens,
resulting in differences in K-Ras mutations frequencies and in
prognostic/predictive values of such mutations. Besides classical
sequencing, K-Ras mutations could be detected by mutation-
specific oligonucleotide hybridisation, PCR followed by restriction
fragment length polymorphisms analysis, single-strand conforma-
tion polymorphisms analysis or mutant allelic-specific amplifica-
tion. These procedures involve multiple steps and/or are
time-consuming. Therefore, they are impracticable for routine
clinical use.
To detect a minimal amount of mutant DNA in clinical
samples, peptide-nucleic-acid (PNA) oligomers have been devel-
oped (Orum et al, 1993). PNAs are non-extendable oligonucleo-
tides in which the ribose-phosphate backbone is replaced by
2-aminoethyl glycine units linked by amide bonds. In PNA-
mediated PCR clamping, PNA oligomers suppress the amplifica-
tion of the complementary sequence confined by a pair of DNA
oligonucleotide primers because PNA are not substrate for
DNA polymerase. The PNA-clamped probe assay is more sensitive
than direct sequencing, with the ability to detect mutations in
samples containing less than 1% mutant alleles (Nagai et al, 2005;
Pao and Ladanyi, 2007). Using this method, c-Kit point mutations
have been detected in skin biopsy samples from patients
with urticaria pigmentosa (Sotlar et al, 2003). Such a technique
has been applied to search for K-Ras mutations in various tumour
samples (Sun et al, 2002; Chen et al, 2004; Taback et al, 2004;
Da ¨britz et al, 2005; Luo et al, 2006; Miyake et al, 2007). This
method was also used to detect EGFR mutations in NSCLC (Nagai
et al, 2005; Soh et al, 2006; Sutani et al, 2006; Tanaka et al, 2007;
Miyanaga et al, 2008).
As NSCLC, in particular adenocarcinoma, could often be mixed
with normal cells, the aim of this study was to estimate the
possibility to increase the sensitivity of the detection of K-Ras
mutations on an EGFR-targeted naive NSCLC cohort, even in cases
of low tumour cellularity and to evaluate its routine clinical
usefulness. To be able to compare the results of detection of K-Ras
mutations by a sensitive technique and by direct sequencing, we
chose to work on frozen samples of NSCLC. We conducted this
study to establish a one-step real-time PCR method that combines
fluorescent hybridisation probes PCR without or with competing
wild-type PNA 17-mer and melting curve analysis for the detection
of K-Ras mutations at codon 12 and 13, in a cohort of 114
consecutive surgical frozen NSCLC tumour tissues.
MATERIALS AND METHODS
Patients
Anonymised frozen samples from 114 routine consecutive NSCLC
patients surgically treated were obtained from the Biological
Resource Center of the University Hospital of Strasbourg, in
protocols approved by the institutional review board. Stage was
defined as recommended (Moutain, 1997). All patients are chemo-
and targeted drug naive at the time of surgery. All the patients are
non-Asian. The patients included 91 men and 23 women. Only
seven (6%) of the patients were never smokers. The observation
period ranged from 1 to 82 months, with a median follow-up of 26
months. Patients’ characteristics are summarized in Table 1.
Tumour and paired normal lung peripheral tissue samples
obtained at the time of surgery, were immediately stored at
 801C. Tumours were histologically classified according to the
World Health Organization guidelines and scored for differentia-
tion (Travis et al, 2004). Three haematoxylin and eosin-stained
sections of frozen tissues were reviewed by a pathologist to
evaluate the percentage of tumour cells, at the beginning, middle
and end of the frozen tissues. The percentage of tumour cells
corresponds to the number of tumour cells reported to the number
of all the cells (tumour and non-tumour cells) analysed on a slide.
Almost half of the patients presented less than 50% of tumour cells.
Histological characteristics are summarized in Table 1.
DNA extraction from frozen lung cancer tumours
Genomic DNA was isolated using conventional techniques with
QIAamp DNA kit (Qiagen, Courtaboeuf, France). To validate the
percentage of tumour cells assessed by the pathologist in the
Table 1 Patients’characteristics
All NSCLC ADC/BAC SCC
All 114 55
a 59
Age (years): mean (s.d.) 61 (10) 61 (10) 61.5 (10)
Gender
Men 91 (80%) 37 (68%) 54 (91.5%)
Women 23 (20%) 18 (33%) 5 (8.5%)
Current/former smoker 106 (93%) 47 (87%) 59 (100%)
Never-smoker 7 (6%) 7 (13%) 0 (0%)
Stage pTNM
I–IIIA 99 (87%) 45 (82%) 54 (91.5%)
IIIB–IV
b 15 (13%) 10 (18%) 5 (8.5%)
Histologic differentiation
Well/moderate 74 (65%) 28 (57%) 46 (80%)
Poor 32 (28%) 21 (43%) 11 (19%)
Tumour cell count
o50% 52 (46%) 28 (51%) 24 (41%)
X50% 62 (54%) 27 (49%) 35 (59%)
Lung cancer relapse
Yes 52 (45%) 28 (54%) 23 (39%)
No 60 (53%) 24 (46%) 36 (61%)
Lung cancer death
Yes 53 (46.5%) 28 (53%) 25 (42%)
No 59 (52%) 25 (47%) 34 (58%)
NSCLC¼non-small cell lung cancer; ADC¼adenocarcinoma; BAC¼bronchiolo-
alveolar carcinoma; SCC¼squamous cell carcinoma. Clinical and pathological
features of 114 NSCLC patients with NSCLC, classified by histological subtypes.
aOf whom eight BAC features.
b7 stages IV with unique metastasis.
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sfrozen samples, paired tumour and normal DNA were amplified by
fluorescent polymerase chain reaction (PCR) for microsatellite
(MS) analysis with a panel of markers distributed among the
genome on 13 chromosomes frequently altered in NSCLC (data not
shown). Detailed MS and PCR conditions are available upon
request.
DNA sequencing analysis
The mutational status of K-Ras (codon 12,13) was performed using
40ng of genomic DNA amplified by PCR in 25ml reaction mix
containing 1.25U Fast Start High Fidelity Taq (Roche), 0.2mM
dNTP, 1.5mM MgCl2, and 0.2mmo fK-Ras F and K-Ras R I primers
(Table 2). After an initial denaturation (2min at 941C), a touch
down protocol was used as follows: 10 cycles with a decreased
hybridisation temperature from 61 to 581C every two cycles. The
subsequent 35 cycles were performed as follows: 50s at 931C, 50s
at 551C, and 1min 30s at 721C, followed by a final extension period
of 10min at 721C. All PCR products were verified by electrophoresis
on agarose gels. After purification (Microcon-PCR Filter Unit,
Millipore, Paris, France), the PCR products were sequenced (Big
Dye Terminator v1.1 Cycle sequencing kit, Applied Biosystems,
Forster City, CA, USA) and analysed on ABI PRISM 3100 Genetic
Analyser (Applied Biosystems). The GB sequence of human K-Ras
(L00045) was used as a reference for sequence analysis (Seqscape
v2.5, Applied Biosystems). All sequencing reactions were
performed in both forward and reverse directions, and all
mutations were confirmed by sequencing a second independent
PCR product. As expected, by direct sequencing technique for K-
Ras mutation analysis, K-Ras mutations were reproducibly
detectable at a dilution of 25% of mutated DNA into normal
DNA (data not shown). All the mutated K-Ras DNA were also
sequenced for EGFR mutation analysis as described earlier (Beau-
Faller et al, 2008).
Real-time PCR and melting curve analysis,
clamped-probe assay
Primers were chosen to amplify a specific 243-bp genomic
fragment from K-Ras codon 12 and 13. Hybridisation FRET
probes were designed complementary to wild-type sequence of
codon 12 and 13. The anchor probe was 50-labeled with LC-Red 640
and 30 phosphorylated, and the sensor probe was 30-labeled with
fluorescein. The PNA oligomer covered codons 10–14 wild-type
sequence. Sequences of primers (Eurogentec, Lie `ge, Belgium),
probes (Timolbiol, Berlin, Germany), and 17 mer-PNA (Euro-
gentec, Lie `ge, Belgium) are listed in Table 2. They are represented
in Figure 1. Real-time PCR was performed with 20ng of genomic
DNA, in a final volume of 20ml containing Light Cycler Fast
Start DNA Master Hyb Probe (Roche Diagnostics, Mannheim,
Germany), 3mM MgCl2, 0.4mM of each primers K-Ras, 0.4mM
of K-Ras hybridisation sensor probe and 0.2mM of K-Ras
Table 2 DNA sequences of primers, PNA oligomer, and probes for
detecting K-Ras mutations
Name
DNA (50–30)o rP N A
(NH2-CONH2) sequence
a
Position,
b
nt
K-Ras F
c GGAGTATTTGATAGTGTATTAACCT 9–33
K-Ras R I AGAATGGTCCTGCACC 251–236
K-Ras R II GTCCTGCACCAGTAATATGC 244–226
Anchor LC-Red 640-ACTACCACA
AGTTTATATTCAGTCATTTTCAGCAGG-Ph
121–86
Sensor CCTACGCCACCAGCTC-Flu 138–124
PNA CCTACGCCACCAGCTCC 138–122
aThe 30 end of the anchor probe was phosphorylated to prevent probe elongation by
Taq polymerase during PCR. Underlined, nucleotide complementary to wild-type
bases of codon 12 and 13.
bThe base numbering is according to GenBank accession
no L00045.
cF¼forward; R¼reverse; Flu¼fluorescein; LC-Red¼LightCycler-Red;
Ph¼phosphorylated; R I: K-Ras reverse primer used for Light-cycler analysis and
classical sequencing; R II: K-Ras reverse primer used for sequencing of PNA–PCR
products.
Codon 12, Codon 13 
X X 
PNA (17-mer) 
Sensor 3′ fluorescein 
Anchor  5′LC Red 
K-RasF 
K-Ras R 
Figure 1 Schematic representation using PNA-mediated PCR for
detection of mutant K-Ras. Relative positions of PCR primers (K-Ras F, K-
Ras R), wild-type hybridisation probes (Anchor, Sensor) and peptide-
nucleic-acid (PNA) for K-Ras mutations detection at codons 12 and 13.
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Figure 2 Serial dilution experiments showing the sensitivity of the
alternative techniques for K-Ras mutation detection: hybridisation assay
without PNA (A) and PNA-clamped probe assay (B). DNA from A549
(lung adenocarcinoma) cell line, which harbours an homozygous K-Ras
mutation (G12S), was diluted into DNA from a wild-type K-Ras HT29 cell
line.
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shybridisation anchor probe, without or with 0.1mM PNA oligomer.
After the initial denaturation step at 951C for 10min, a touch down
amplification was performed consisting of a denaturation at 951C
for 10, 7s at 761C, then 10 cycles with touchdown annealing for
15s from 65 to 551C (decreasing 21C/two cycles) and elongation at
651C for 20s. This step was followed by 28 cycles: 951C for 10s,
761C for 7s, 501C for 15s, 651C for 20s. Melting curve analysis was
performed by increasing temperature from 40 to 951C with a
transition rate of 0.251Cs
 1. Fluorescence data were analysed
using the Light Cycler software (software version 3.5, Roche
Diagnostics). Mutation analysis for each tumour sample was
performed at least two times. PNA–PCR products from all samples
that gave positive results by the clamped-probe assay was
sequenced to confirm and precise the type of K-Ras mutation.
Controls
DNA from a lung cancer cell line A549 with a homozygous K-Ras
codon 12 mutation (c.34G4A, G12S) was used for homozygous
K-Ras mutation positive control. One negative control (DNA from
colon cancer cell line HT29 of colon carcinoma with wild-type
K-Ras sequence) and a no template negative control (as control for
contamination) were processed in parallel. We evaluate the
sensitivity of the developed alternative methods by serially diluting
DNA from A549 mutated K-Ras cell line in the DNA of wild-type
K-Ras HT29 cell line (Figure 2).
Statistical analysis
A total number of patients to be tested by PNA–PCR clamp was
decided to be more than 100 patients because about 15–20% of
NSCLC patients were reported to have K-Ras mutations in
previous articles (Mascaux et al, 2005). Statistical analysis using
w
2 test or exact test (type Fisher’s test) if appropriate with exact
P-values was used to compare the qualitative data. Where
appropriate, continuous variables were categorized before analysis.
The date of point was 30 April 2008. The Kaplan–Meier method
was used to estimate the probability of event-free survival and the
log-rank test to detect the difference in survival curves. Cox’s
proportional hazard models were used to determine the impact of
patient characteristics on event-free survival. All statistical
calculations were performed with the Statistical Package for the
Social Science (SPSS) (number 15.0) statistical software.
RESULTS
Sequence analysis of NSCLC samples
We first analysed the 114 routine samples by direct sequencing for
K-Ras mutation detection. By this technique, 11 (10%) of the 114
cases showed a K-Ras mutation at codon 12 or 13, represented by
five mutations G12C, two mutations G12D, two mutations G12V,
one mutation G12R and one mutation G12A (Tables 3 and 4).
Determination of the sensitivity of the hybridisation-probe
assay and clamped-probe assay
The tumour cell count was lower than 50% in 52 patients, and
among them lower than 25% in 15 patients (Table 1). To further
improve the detection of K-Ras mutations in comparison with
direct sequencing, we developed real-time PCR with wild-type
hybridisation probes without or with PNA-mediated clamped PCR.
Table 4 Clinical and biological characteristics of K-Ras NSCLC-mutated patients
No Sex
Age
(years)
Histological
type
Tumour cells
count (%) Stage Relapse
EFS
(months)
Technique using for
K-Ras mutation detection
Type of
K-Ras mutation
77 M 51 ADC 90 IIB Yes 2 SQC G12C
108 F 52 ADC 70 IIIA Yes 14 SQC G12C
118 M 68 SCC 60 IB No 25 SQC G12D
24 M 58 ADC 60 IB No 39 SQC G12C
1109 M 60 ADC-BAC 50 IIB No 52 SQC G12A
50 M 54 SCC 50 IA Yes 20 SQC G12D
1111 M 66 SCC 50 IA Yes 8 SQC G12V
1124 F 44 ADC 50 IIIA Yes 5 SQC G12R
1104 M 70 ADC-BAC 40 IIIB No 44 SQC G12C
1118 F 53 ADC 40 IV Yes 1 SQC G12C
9915 M 60 SCC 40 IIB Yes 3 SQC G12V
22013 F 60 SCC 90 IB No 18 HYB G12C
52 M 44 ADC 70 IIIA Yes 22 HYB G12C
63 F 44 ADC 50 IA No 49 HYB G12D
91 M 67 ADC 15 IB No 18 HYB G12C
1126 M 74 ADC 1 IA No 29 HYB G13C
1116 M 55 ADC 50 IIB No 26 PNA G12S
22006 M 56 ADC 50 IIIA Yes 14 PNA G12C
1103 M 76 ADC 10 IIIA Yes 8 PNA G12D
121 M 45 SCC 1 IB No 49 PNA G12C
102 M 56 ADC 1 IIIA Yes 39 PNA G12D
ADC¼adenocarcinoma; BAC¼bronchioloalveolar carcinoma; SCC¼squamous cell carcinoma EFS¼event-free survival; SQC¼results obtained by direct sequencing;
HYB¼results obtained by hybridisation probe assay; PNA¼results obtained by clamped-probe assay.
Table 3 Types of K-Ras mutations found in 114 NSCLC tumours
(Codon)mutation
a
(aminoacid change)
Sequencing
(%)
b
Hybrisation
(%)
b
PNA
(%)
b
(12) GGT-AGT (Gly-Ser) 0 (0) 0 (0) 1 (5)
(12) GGT-CGT (Gly-Arg) 1 (9) 1 (6) 1 (5)
(12) GGT-TGT (Gly-Cys) 5 (45.5) 8 (50) 10 (48)
(12) GGT-GAT (Gly-Asp) 2 (18) 3 (19) 5 (24)
(12) GGT-GCT (Gly-Ala) 1 (9) 1 (6) 1 (5)
(12) GGT-GTT (Gly-Val) 2 (18) 2 (12.5) 2 (9.5)
(13) GGC-TGC (Gly-Cys) 0 (0) 1 (6) 1 (5)
K-Ras mutation 11 16 21
Wild-type 103 98 93
Total 114 114 114
aAltered bases are underlined.
b(%) Percentage of mutation type reported to
mutated cases.
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sWe assessed the sensitivity of these assays by testing homozygous
G12S K-Ras mutated A549 cell line DNA serially diluted into DNA
from wild-type K-Ras HT29 cell line DNA. By hybridisation-probe
assay, the mutations were reproducibly detectable at a dilution of
10% of mutated DNA into wild-type DNA and by the clamped-
probe assay, at a dilution of 1% of mutated DNA into wild-type
DNA (Figure 2). Indeed, in our conditions, addition of PNA allows
to increase the threshold detection of K-Ras mutation by a
magnitude of 10.
Hydridisation-probe and clamped-probe assays for
detecting K-Ras mutations. Comparison with direct
sequencing
All the 114 patients were then analyzed for K-Ras mutations by
hybridisation-probe assay and clamped-probe assay (Table 2). As
expected, the 11out of 114 (10%) tumours with a K-Ras mutation at
codon 12 or 13 detected by direct sequencing, were also detected
by hybridisation-probe/clamped-probe assays. However, five
tumours with wild-type K-Ras assessed by direct sequencing
presented K-Ras mutations when using the hybridisation-probe
assay. Remarkably, five other tumours with wild-type K-Ras
assessed by direct sequencing and by the hybridisation-probe
assay presented K-Ras mutations when using clamped-probe assay
alone. As expected, all the positive samples detected by hybridisa-
tion-probe assay were also positive for clamped-probe assay. Thus,
these sensitive techniques allowed an increase in detection of
K-Ras mutations from 11 out of 114 patients (10%) by direct
sequencing to 21 out of 114 (18%) (Po0.005). To confirm the
mutations in the 10 tumours only detected by these sensitive
techniques and to identify precisely the type of K-Ras mutation, all
PNA–PCR products were directly sequenced for codon 12 and 13
of K-Ras. We identified five mutations G12C, three mutations
G12D, one mutation G12S and one mutation G13C with
hybridisation-probe/clamped-probe assays (Tables 3 and 4,
Figure 3).
Among the K-Ras mutated tumours diagnosed only by
hybridisation/PNA techniques, five had a percentage of tumour
cells effectively lower than required for classical sequencing. The
tumour cellularity of these tumours was 15% (one patient), 10%
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Figure 3 Representative melting curves obtained by hybridisation and clamped-probe assays. On the right side, paired electropherograms obtained by
sequencing of a PCR product, without and with PNA. (A) K-Ras mutation (G12D) diagnosed by the two alternative techniques: hybridisation probe and
clamped-PCR assays (No. 63). (B) K-Ras mutation (G12D) only diagnosed by the most sensitive technique: clamped-PCR (No. 1103).
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s(one patient) and less than 10% (three patients). K-Ras mutations
in two of these tumours were detected by hybridisation-probe
assay and three others by clamped-probe assay only. In another
hand, five K-Ras mutated tumours diagnosed only by hybridisa-
tion/PNA techniques, presented a percentage of tumour cells
usually sufficient for direct sequencing, suggesting the presence of
mutated tumour subclones.
Clinical data and K-Ras mutations detected by the
different methods
Then, we asked for the clinical usefulness of K-Ras mutations
detected by these sensitive techniques. Our cohort of 114 surgically
treated NSCLC patients were represented by 55 ADC and 59 SCC
(Table 1). The 11 K-Ras mutations detected by direct sequencing
were found in seven ADC (two with BAC features) and in four SCC
(Tables 1 and 4). The 10 additional K-Ras mutations detected by
hybridisation/PNA methods were observed in eight ADC and in
two SCC. Overall, the 21 K-Ras mutated patients, 16 males and five
females, 15 ADC and six SCC, have tumours from all stages and
from current/former smokers. In adenocarcinoma, K-Ras mutation
frequency increased from 7 out of 55 (13%) by direct sequencing to
15 (27%) by clamped-PCR (Po0.005). If there is no correlation
between K-Ras mutation frequency detected by direct sequencing
and histological subtypes, a correlation was found between K-Ras
mutation frequency detected by hybridisation/PNA methods and
ADC histological subtype (P¼0.01). Survival analysis showed that
the presence of K-Ras mutations diagnosed by direct sequencing
are a weak prognostic marker of poorer outcome (median EFS 14
months vs 47 months, HR¼1.57, CI 95%: 0.77–3.84, P¼0.08). By
contrast, when taking into account all the K-Ras mutations
detected by the three techniques, our results failed to confirm
K-Ras oncogenic activation as a significant marker of poor
prognosis after surgery for NSCLC (median EFS 16 months vs 47
months, HR¼1.19, CI 95%: 0.61–2.32, NS) (Figure 4).
DISCUSSION
Surgical tumour specimens of NSCLC may contain a lot of normal/
inflammatory cells. The presence of a high percentage of normal/
inflammatory cells could lead to ‘false-negative’ results when
mutations were detected by direct sequencing. A recent commen-
tary synthetically addresses the question of the ideal method for
EGFR mutation testing in lung cancer (Pao and Ladanyi, 2007), but
no such data are available for K-Ras. We developed a quick, cheap
and sensitive method for detecting K-Ras mutations from routine
surgical specimens of NSCLC without removing contaminating
normal cells by macro/micro dissection.
PNA–PCR clamp method can rapidly (within 2h) detect K-Ras
mutations using a low quantity of DNA. By contrast to other PNA
studies, we used wild-type fluorescent-labelled hybridisation
probes allowing rapid and high-sensitive detection of all the
K-Ras mutations (Sun et al, 2002; Chen et al, 2004; Taback et al,
2004; Da ¨britz et al, 2005; Luo et al, 2006; Miyake et al, 2007). Only
one pair of primers and one pair of probes are required to detect
all possible mutations in codons 12 and 13 of the K-Ras gene. The
detected fluorescence signal corresponds to the amplified mutant
DNA and can be analysed by a subsequent melting curve analysis.
If requested, the PNA–PCR products are available to precisely
identify the mutated nucleotide. All these advantages greatly
simplify the manipulating procedure.
The sensitivity of direct sequencing depends on the percentage
of tumour cells in the analysed sample, generally up to 50%
tumour cells is requested with a detection threshold of 25% mutant
DNA into a wild-type environment (Pao and Ladanyi, 2007;
Eberhard et al, 2008). The sensitivity of our assays is 10 and 1% of
mutant DNA for hybridisation-probe assay and for clamped-probe
assay, respectively, and might correspond to a more sensitive test,
applicable for routine purposes without macro or micro dissection.
Another new rapid method for mutated EGFR and K-Ras detection
by high resolution melting analysis (HRM) has been recently
reported (Do et al, 2008). Even HRM is a promising method, it can
be compromised by a low proportion of tumour cells in the
analysed sample and by the difficulty to detect homozygous
mutations, as the sensitivity of K-Ras mutations detection was only
5–10%. Among the 10 new K-Ras mutated patients detected by
these most sensitive methods, half presented a percentage of
tumours cells under the level usually required for direct
sequencing. Thus, even in a surgical cohort of NSCLC tumour
samples, there is a risk of false-negative K-Ras mutated patients
when they were analysed by direct sequencing. The rapidity and
sensitivity of our sensitive technique could lead us to propose this
test for routine K-Ras mutation detection, that is, bronchial
biopsies in NSCLC.
In our study, the 10 new K-Ras-mutated cases presented clinical/
biological characteristics usually associated with K-Ras mutations
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Figure 4 Kaplan–Meier curves for event-free survival (months) of 114
NSCLC tumours. (A) Stratified according to K-Ras mutation analysed by
direct sequencing (median EFS 14 months vs 47 months, HR¼1.57, CI
95%: 0.77–3.84). (B) Stratified according to K-Ras mutation analysed by
PCR clamp assay (median EFS 16 months vs 47 months, HR¼1.19, CI 95%:
0.61–2.32).
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sin NSCLC (Ahrendt et al, 2001; Broermann et al, 2002; Sugio et al,
2006; Tam et al, 2006). Remarkably, none of the five new K-Ras
mutated patients with more than 50% of tumour cells, presented
an EGFR mutation (exon 18, 19, 20, 21) (data not shown).
Interestingly, if K-Ras mutations diagnosed by direct sequencing
appeared to be a prognostic marker of poorer outcome in our
cohort of surgically treated NSCLC patients, this tendency is not
more observed when we considered K-Ras mutations diagnosed by
the two other techniques (hybridisation probe alone, or with
clamped-PCR). Our survival analysis is nevertheless limited by the
relatively short follow-up with fewer than half of the patients
having relapsed or died. Accordingly, a recent study (JBR.10)
showed that mutations of K-Ras gene were neither prognostic for
survival nor predictive of a differential benefit from adjuvant
chemotherapy in stage IB and II NSCLC (Tsao et al, 2007). In this
study, the tumour cellularity was enriched by microdissection, and
using allelic-specific oligonucleotide hybridisation, they failed to
confirm K-Ras oncogenic activation as a significant marker of poor
prognosis after surgery for NSCLC. The lack of prognostic value of
all the K-Ras mutated cases could be explained by the fact that in
cases of mutation detected by sensitive techniques, the real
percentage of K-Ras mutated cells could be too low, under a
threshold with immediate clinical significance. Further studies are
required to precisely determinate the significant prognostic
threshold of K-Ras mutated cells.
In our study, half of the new K-Ras mutated cases diagnosed
only by sensitive techniques, presented a percentage of tumour
cells above the threshold usually required for direct sequencing.
These results suggest the presence of mutated subclones in the
tumour. In fact, direct sequencing could fail to detect mutated
subclones (Pao and Ladanyi, 2007). Some EGFR-mutated sub-
clones were already detected in NSCLC when EGFR T790M
mutations have been analysed with sensitive techniques (Inukai
et al, 2006). It was suggested that the possible presence of such
mutations at a low frequency in NSCLC tumours before EGFR-
targeted therapy might affect the tumour response or the event-
free survival after targeted treatments. Recently, K-Ras mutations
detected by allelic discrimination on tumour DNA, have been
demonstrated to be an independent prognostic factor in patients
with advanced colorectal cancer treated with cetuximab (Lie `vre
et al, 2008). To our knowledge, no predictive studies have been
realised to identify K-Ras mutated subclones in NSCLC, but the
presence of such mutated subclones could explain some cases of
secondary EGFR-targeted therapy resistance. Therefore, it would
be important to evaluate the predictive value of such K-Ras
mutated tumour subclones, particularly in stabilised or progres-
sive cases treated by targeted EGFR therapy.
Consequently, the percentage of tumour cells in the analyzed
sample as well as the threshold of mutation detection of the
currently molecular test appeared to be two essential data to better
understand the significance (i.e., prognostic or predictive factor) of
the detected mutation. Indeed, in our cohort of surgical specimen,
53 (46.5%) of our routine consecutive patients presented a
percentage of tumour cells under the value (50%) classically
required for direct sequencing; and in addition, some patients with
a percentage of tumour cells sufficient for direct sequencing,
appeared to have K-Ras mutations at a low frequency. In the first
type of tumours, a sensitive technique will detect low level of K-Ras
mutations with finally a number of K-Ras mutated tumour cells
which could have clinical usefulness; in the second type of
tumours, sensitive technique will detect K-Ras-mutated subclones
of which clinical usefulness has still to be explored.
In conclusion, our study allows us to propose an easy and
sensitive method for rapid analysis of K-Ras mutations in NSCLC
tumours. This sensitive technique could be helpful for specimens
of lung cancer without removing contaminating normal cells,
mostly in the setting of NSCLC, in which diagnoses are often based
on bronchial biopsies or cytologic specimens. The prognostic value
of such sensitive detected K-Ras mutations when tacking into
account the tumour cellularity, has still to be evaluated on an
increased number of surgically treated lung cancer patients, taking
into account the frequency of mutated allele in the sample
depending on the tumour cellularity. Furthermore, predictive
value of low represented K-Ras mutations need to be assessed in
lung cancer patients treated by targeted anti-EGFR treatments, to
optimise such treatments in NSCLC patients.
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